Lipopeptide Ab

Scotia Lipidteknik Ab

Pharmacia Ab

Asarina Pharma Ab

Lipidor Ab

Pep-tonic Medical Ab

Astra Ab

Scotia Holdings Plc.

Lidds Ab

Biolipox Ab

Cebix Incorporated

Adenovir Pharma Ab

Meda Ab

Umecrine Mood Ab

Anders Carlsson

Conny Bogentoft

Bengt Herslof

Johan Heilborn

Mona Ståhle-Bäckdahl

Torbjörn Bäckström

Dan Markusson

Jan Holmbäck

Olov Sterner

Hans Lennernäs

Niklas Axén

John Wahren

Arne Brodin

Ulf Ellervik

Kerstin Uvnäs-Moberg

Lars Lindmark

Lars Åke Malmsten

Erik Sundquist

Martin Nicklasson

Karin Bohlinder

Snezana Petrovic-Kallholm

Janet Tomlin

Marina Delogu

Lisbeth Rydhag

Karolina Aplander

Lena Pereswetoff-Morath

Niklas AXÉN

Lars ÅKe Malmsten

Torbjørn Bjerke

Mona St Hle-Bäckdahl

Described is an aqueous composition comprising:

Composition for treating and/or preventing fungal infections

Described is a urogenital cleansing composition that includes a non-ionic cellulose ether, an aqueous solvent, a triglyceride oil and a pH-regulating agent, wherein the urogenital cleansing composition does not contain any additional emulsifier and have a pH within the range of from 3 to 4 and wherein the pH-regulating agent is a lactate buffer.

Urogenital cleansing composition

It is provided a pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one, at least one sterol or an ester thereof and a mixture of acylglycerols with a solid fat content of less than 25% at 25&#xb0; C. and 0% at 37&#xb0; C. In addition it is provided a method for preparing the pharmaceutical composition.

Pharmaceutical composition comprising 3-beta-hydroxy-5-alpha-pregnan-20-one with improved storage and solubility properties

A lipid layer forming composition comprises a volatile silicone oil of a boiling point above 180&#xb0; C., a polar lipid, optionally a C-Caliphatic alcohol, optionally a pharmacologically or cosmetically active agent or a protective agent. The lipid layer forming composition can be applied to a biological surface by spraying, dipping or brushing to form a stable polar lipid layer on the surface.

Lipid layer forming composition for administration onto a surface of a living organism

There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.

Method and composition for treating rhinitis

Carboxymethylcellulose, notably sodium carboxymethylcellulose or other alkali metal or alkaline earth metal salts of carboxymethylcellulose, are employed to control solidification time of compositions comprising one or more bioresorbable ceramics, notably a hydratable calcium sulphate, in order to facilitate preparation of a ready-to-use composition for inserting into the body by injection.

Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics

Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Use of the cathelicidin LL-37 and derivatives thereof for wound healing

The present invention provides a pharmaceutical composition for the sustained release of C-peptide. The composition is in the form of a gel containing C-peptide. The gel formation is achieved by the adjustment of pH of the composition and/or by addition of divalent metal ions. The composition does not include any other gel-forming agents. Methods for producing the composition, medical uses of the composition and products containing two or more gel compositions as a combined preparation are also encompassed.

Sustained release preparation of pro-insulin C-peptide

Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus. 

Antiviral compounds

Use of the cathelicidin LL-37 and derivatives therof for wound healing

Use of the antimicrobial cathelicidin peptide ll-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithalial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.

Growing community of inventors

Stockholm, Sweden

Anders Carlsson